

Summary Public Assessment Report

Lymecycline Glenmark (lymecycline)

SE/H/2129/01/DC

Summary Public Assessment Report

Lymecycline Glenmark
tetracycline, lymecycline

Capsule, hard, 300 mg

This is a summary of the public assessment report (PAR) for Lymecycline Glenmark. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Lymecycline Glenmark and what is it used for?

The product is a 'generic medicine'. This means that it is similar to a 'reference medicine' already authorised in the European Union (EU) called Tetralysal.

The product is used in the treatment of the following infections in adults and children over 12 years of age:

- Moderate to severe acne.
- Sudden worsening of bronchitis
- Pneumonia
- Urogenital infection (infection in urinary organs or the genitals) caused by a type of bacteria called Chlamydia.

How does Lymecycline Glenmark work?

The product is an antibiotic.

How is Lymecycline Glenmark used?

The pharmaceutical form is capsule, hard, for oral use.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Lymecycline Glenmark have been shown in studies?

Because the product is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Tetralysal.

Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the possible side effects from Lyme cycline Glenmark?

Because the product is a generic medicine, its benefits and possible side effects are taken as being the same as the reference medicine.

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Lyme cycline Glenmark approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered to be bioequivalent to the reference medicine Tetralysal. Therefore, the Swedish Medical Products Agency decided that, as for Tetralysal, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Lyme cycline Glenmark?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Lyme cycline Glenmark

The full PAR for Lyme cycline Glenmark can be found on the following website: <http://mri.medagencies.org/Human/>. For more information about treatment with Lyme cycline Glenmark, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2022-08.